Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
The report estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
The highest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in the NDA/BLA phase.
Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.
High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, and an expected supplemental BLA filing for Tecartus.
The overall likelihood of approval of a Phase I hematologic asset is 8.7%, and the average probability a drug advances from Phase III is 58.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.
The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
Novartis has the highest number of completed clinical trials for ALL, with 47 trials.
Novartis also leads industry sponsors with the highest overall number of clinical trials for ALL
Key Topics Covered:
Stem cell transplant
RECENT EVENTS AND ANALYST OPINION
Blincyto for ALL (December 10, 2019)
GC022 for ALL (December 7, 2019)
Blincyto for ALL (September 24, 2019)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
ADC Therapeutics In Asia JV, License Deal With Overland
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
For more information about this report visit https://www.researchandmarkets.com/r/lhduvf
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900